ArticleJournal of gastrointestinal oncology2023

The role of ramucirumab plus paclitaxel as second-line therapy after failure of nivolumab plus doublet chemotherapy in patients with advanced gastric cancer.

Youngkyung Jeon et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.